Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals
Soligenix, Inc. (SNGX)
NASDAQ:AMEX Investor Relations:
soligenix.com/investors
Company Research
Source: PR Newswire
PRINCETON, N.J., April 16, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has executed an agreement for the exclusive worldwide license of CoVaccine HT™, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals ("BTG"), a division of Boston Scientific Corporation (NYSE: BSX), for the fields of SARS-CoV-2, the cause of COVID-19 and pandemic flu. CoVaccine HT is a novel adjuvant, which has been shown to enhance both cell-mediated and antibody-mediated immunity. Soligenix and its collaborators, including the University of Hawai?i at Manoa and Dr. Axel Lehrer, have successfully demonstrated the utility of CoVaccine HT in the development of its heat stable filovirus vaccine program, with vaccine candidates against Ebola and Marburg virus disease. Given this previous success, CoVaccine HT will
Show less
Read more
Impact Snapshot
Event Time:
SNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNGX alerts
High impacting Soligenix, Inc. news events
Weekly update
A roundup of the hottest topics
SNGX
News
- Cutaneous T-cell Lymphoma Market Landscape Report 2024: Comprehensive Insights About 25+ Companies and 30+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma [Yahoo! Finance]Yahoo! Finance
- Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell LymphomaPR Newswire
- Soligenix to Present at November 21st Virtual Investor Summit Microcap Event [Yahoo! Finance]Yahoo! Finance
- Soligenix to Present at November 21st Virtual Investor Summit Microcap EventAccesswire
SNGX
Sec Filings
- 11/8/24 - Form 424B3
- 11/8/24 - Form 424B3
- 11/8/24 - Form 424B3
- SNGX's page on the SEC website